FN-1501

Generic Name: FN-1501

Brand Names: Cellcept, Myfenax, CellCept, Mycophenolate mofetil Teva, Myclausen

Drug Type: Small Molecule

Chemical Formula: C_₂₂H_₂₅N_₉O

CAS Number: 1429515-59-2

Unique Ingredient Identifier: 6MC966B505

Background: Mycophenolate mofetil, also known as MMF or CellCept, is a prodrug of mycophenolic acid, and classified as a reversible inhibitor of inosine monophosphate dehydrogenase (IMPDH). This drug is an immunosuppressant combined with drugs such as Cyclosporine and corticosteroids to prevent organ rejection after hepatic, renal, and cardiac transplants. It is markete...

Indication: Mycophenolate mofetil is indicated in combination with other immunosuppressants to prevent the rejection of kidney, heart, or liver transplants in adult and pediatric patients ≥3 months old. Mycophenolate mofetil may also be used off-label as a second-line treatment for autoimmune hepatitis that has not responded adequately to first-line therapy. Other off-l...

Associated Conditions: Transplanted Organ Rejection

Associated Therapies: -

Clinical Trials

A Study of Mycophenolate Mofetil Combined With Glucocorticoid Therapy in Relapse Vogt-Koyanagi-Harada Disease

Recruiting

Conditions: Mycophenolate Mofetil
Vogt-Koyanagi-Harada Disease

Interventions: Drug: Mycophenolate Mofetil

First Posted Date: 2022-11-28

Last Posted Date: 2023-12-07

Lead Sponsor: Tianjin Medical University

Target Recruit Count: 15

Registration Number: NCT05627739

Locations: 🇨🇳
xiaomin Zhang, Tianjin, Tianjin, China

De-escalated Cyclophosphamide (PTCy) and Ruxolitinib for Graft-versus-Host Disease (GVHD) Prophylaxis

Phase 2

Recruiting

Conditions: Graft-versus-host Disease

Interventions: Drug: Cyclophosphamide
Drug: Tacrolimus
Drug: Mycophenolate Mofetil
Drug: Ruxolitinib

First Posted Date: 2022-11-18

Last Posted Date: 2024-10-01

Lead Sponsor: Medical College of Wisconsin

Target Recruit Count: 56

Registration Number: NCT05622318

Locations: 🇺🇸
Froedtert Hospital & the Medical College of Wisconsin, Milwaukee, Wisconsin, United States

Immunosuppressive Treatment in Chronic Virus-Negative Inflammatory Cardiomyopathy

Phase 2

Recruiting

Conditions: Inflammatory Cardiomyopathy

Interventions: Drug: Mycophenolate Mofetil Placebo
Drug: Mycophenolate Mofetil
Drug: Prednisolone Placebo
Drug: Prednisolone

First Posted Date: 2022-10-06

Last Posted Date: 2024-08-16

Lead Sponsor: LMU Klinikum

Target Recruit Count: 130

Registration Number: NCT05570409

Locations: 🇩🇪
Kerckhoff-Klinik GmbH, Bad Nauheim, Germany
🇩🇪
Charité - University Hospital Berlin, Berlin, Germany
🇩🇪
UHF- Universitäres Herz- und Gefässzentrum, Frankfurt, Germany

and more 11 locations

The Pediatric Lupus Nephritis Mycophenolate Mofetil (PLUMM) Study

Phase 2

Recruiting

Conditions: Lupus Nephritis

Interventions: Drug: Mycophenolate Mofetil

First Posted Date: 2022-09-13

Last Posted Date: 2024-10-16

Lead Sponsor: Children's Hospital Medical Center, Cincinnati

Target Recruit Count: 105

Registration Number: NCT05538208

Locations: 🇺🇸
Emory Children's Center, Atlanta, Georgia, United States
🇺🇸
University of California, San Francisco, San Francisco, California, United States
🇺🇸
Children's Hospital Colorado, Aurora, Colorado, United States

and more 16 locations

MMF Versus CYC in the Induction Therapy of Pediatric Active Proliferative LN

Phase 4

Recruiting

Conditions: Mycophenolate Mofetil
Cyclophosphamide
Lupus Nephritis

Interventions: Drug: Cyclophosphamide
Drug: Mycophenolate Mofetil

First Posted Date: 2022-08-10

Last Posted Date: 2022-08-10

Lead Sponsor: Second Xiangya Hospital of Central South University

Target Recruit Count: 224

Registration Number: NCT05495893

Locations: 🇨🇳
the Second Xiangya Hospital of Central South University, Changsha, Hunan, China

Mismatched Related Donor Versus Matched Unrelated Donor Stem Cell Transplantation for Children, Adolescents, and Young Adults With Acute Leukemia or Myelodysplastic Syndrome

First Posted Date: 2022-07-14

Last Posted Date: 2024-12-04

Lead Sponsor: Children's Oncology Group

Target Recruit Count: 435

Registration Number: NCT05457556

Locations: 🇺🇸
Children's Hospital of Alabama, Birmingham, Alabama, United States
🇺🇸
Phoenix Childrens Hospital, Phoenix, Arizona, United States
🇺🇸
Arkansas Children's Hospital, Little Rock, Arkansas, United States

and more 59 locations

Donor Lymphocyte Infusion After Allogeneic Hematopoietic Cell Transplantation for High-Risk Hematologic Malignancies

Phase 1

Recruiting

Conditions: Hematologic Neoplasms

Interventions: Procedure: donor lymphocyte infusion
Drug: Cyclophosphamide
Drug: Busulfan
Drug: Mycophenolate mofetil
Drug: Fludarabine
Drug: Sirolimus

First Posted Date: 2022-04-14

Last Posted Date: 2024-11-25

Lead Sponsor: National Cancer Institute (NCI)

Target Recruit Count: 430

Registration Number: NCT05327023

Locations: 🇺🇸
National Institutes of Health Clinical Center, Bethesda, Maryland, United States

Examining Distinct Immunophenotypes to Validate and Enhance Rational Treatment in Systemic Lupus

Phase 2

Recruiting

Conditions: Systemic Lupus Erythematosus

Interventions: Drug: Placebo for Mycophenolate Mofetil
Drug: Placebo for Voclosporin
Drug: Mycophenolate Mofetil
Drug: Voclosporin

First Posted Date: 2022-04-01

Last Posted Date: 2024-01-19

Lead Sponsor: National Institute of Allergy and Infectious Diseases (NIAID)

Target Recruit Count: 120

Registration Number: NCT05306873

Locations: 🇺🇸
UCLA Medical Center: Division of Rheumatology, Los Angeles, California, United States
🇺🇸
Yale University School of Medicine: Rheumatology, Allergy & Immunology, New Haven, Connecticut, United States
🇺🇸
Emory University School of Medicine: Division of Rheumatology, Atlanta, Georgia, United States

and more 8 locations

Allogeneic Hematopoietic Stem Cell Transplantation for 4/M Neuroblastoma

Phase 2

Not yet recruiting

Conditions: Neuroblastoma

Interventions: Drug: Anti Thymocyte Globulin
Drug: Fludarabine
Drug: Cyclophosphamide injection
Drug: Topotecan
Drug: Melphalan
Drug: Thiotepa
Drug: Busulfan
Drug: Cyclosporine
Drug: Tacrolimus
Drug: Mycophenolate Mofetil
Drug: Methotrexate

First Posted Date: 2022-03-31

Last Posted Date: 2022-07-01

Lead Sponsor: Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University

Target Recruit Count: 64

Registration Number: NCT05303727

Locations: 🇨🇳
Sun Yat-sen Memorial Hospital, Sun Yat-sen University, Guangzhou, Guangdong, China

Mycophenolate Mofetil in Combination With Standard of Care for the Treatment of Glioblastoma

Phase 1

Recruiting

Conditions: Glioblastoma
Recurrent Glioblastoma
Astrocytoma
Glioblastoma, IDH-Wildtype
MGMT-Unmethylated Glioblastoma

Interventions: Drug: Mycophenolate Mofetil
Other: Quality-of-Life Assessment
Radiation: Radiation Therapy
Drug: Temozolomide

First Posted Date: 2022-02-11

Last Posted Date: 2022-08-25

Lead Sponsor: Northwestern University

Target Recruit Count: 60

Registration Number: NCT05236036

Locations: 🇺🇸
Northwestern University, Chicago, Illinois, United States

Drug Development Updates

Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.

© Copyright 2024. All Rights Reserved by MedPath

Home Terms & Conditions Privacy Policy